(Q36845206)

16 August 2017

Brimonidine tartrate: a one-month dose response study (English)

1 reference

16 August 2017

1 reference

Derick RJ

1

1 reference

16 August 2017

Robin AL

2

1 reference

16 August 2017

Walters TR

3

1 reference

16 August 2017

Barnebey HS

4

1 reference

16 August 2017

Choplin N

5

1 reference

16 August 2017

Schuman J

6

1 reference

16 August 2017

Kelley EP

7

1 reference

16 August 2017

Chen K

8

1 reference

16 August 2017

Stoecker JF

9

1 reference

16 August 2017

1 January 1997

1 reference

16 August 2017

1 reference

16 August 2017

104

1 reference

16 August 2017

1

1 reference

16 August 2017

131-136

1 reference

Apraclonidine. A one-week dose-response study

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Short-term Effects of Unilateral 1% Apraclonidine Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Follicular conjunctivitis associated with apraclonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Questions concerning the role of apraclonidine in the management of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Effects of brimonidine on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Reformulation and drop size of apraclonidine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

The effect of topical clonidine on intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930349-2

7 January 2021

10.1016/S0161-6420(97)30349-2

Identifiers

DOI

1 reference

16 August 2017

1 reference